Increased Expression of 5-Lipoxygenase In Glioblastoma Multiforme

  • Mladen Golubic
  • Richard A. Prayson
  • Linda Vargo
  • Judy Bondar
  • Gene H. Barnett
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 525)


Gliomas are the most common primary brain tumors and account for 40% of all central nervous system neoplasms. Glioblastoma multiforme (GBM) is the most malignant glioma and is characterized by highly infiltrative and neurologically destructive growth patterns. Despite new advances in surgical intervention, radiotherapy, chemotherapy, and a variety of molecular target specific therapies, the median survival of patients with GBM did not change in the last two decades. Today, most GBM patients still die in less than a year [1]. Therefore, it is essential to identify novel molecular targets that may be suitable for treatment and prevention of GBM.


Malignant Glioma Glioblastoma Multiforme Malignant Mesothelioma Central Nervous System Neoplasm Human Brain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Caveene WK, DePinho RA: Malignant glioma: genetics and biology of grave matter. Gen Develop, 2001; 15:1311–1333.CrossRefGoogle Scholar
  2. 2.
    Ledwozyw A, Lutnicki K: Phospholipids and fatty acids in human brain tumors. Acta Physiol Hungarica 1992; 79:381–387.Google Scholar
  3. 3.
    Kokoglu E, Tuter Y, Yazici 2, Sandicki KS, Sonmez H, Ulakoglu EZ, Ozyurt E: Profiles of the fatty acids in the plasma membrane of human brain tumors. Cancer Biochem Biophys 1998; 16:301–312.PubMedGoogle Scholar
  4. 4.
    Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001; 61:4375–4381.PubMedGoogle Scholar
  5. 5.
    Simmet T, Luck W, Winking M, Delank WK, Peskar BA: Identification and characterization of cysteinyl-leukotriene formation in tissue slices from human intracranial tumors: evidence for their biosynthesis under in vivo conditions. J Neurochem 1990; 54:2091–2099.PubMedCrossRefGoogle Scholar
  6. 6.
    Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Geatani P, Paoletti P: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989; 49:1505–1058.PubMedGoogle Scholar
  7. 7.
    Funk CD: Prostaglandins and Leukotrienes: Advances in eicosanoid biology. Science 2001; 294:1871–1875.PubMedCrossRefGoogle Scholar
  8. 8.
    Romano M, Catalano A, Nutini M, D’Urbano E, Crescenzi C, Claria J, Libner R, Davi G Procopio A: 5-Lipoxygenase regulates malignant mesothelioma cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15:2326–2336.PubMedCrossRefGoogle Scholar
  9. 9.
    Tong W-g, Ding X-Z, Witt RC, Adrian TE: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Therap 2002; 1:929–935.Google Scholar
  10. 10.
    Boado RJ, Pardridge WM, Vinters HV, Black KL: Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: Evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 1992; 89:9044–9048.PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2000; 91:737–743.CrossRefGoogle Scholar
  12. 12.
    Woods JW, Evans JF, Ethier D, Scott S, Vickers PH, Hearn L, Heibein JA, Charleson S, Dinger II: 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178:1935–1946.PubMedCrossRefGoogle Scholar
  13. 13.
    Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8:467–483.PubMedGoogle Scholar
  14. 14.
    Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exper Therap 1992;261:1143–1146.Google Scholar
  15. 15.
    Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL: Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999; 59:2223–2228.PubMedGoogle Scholar
  16. 16.
    Park YS, Lee JH, Bondar J, Harwalker JA, Safayhi H, and Golubic M: Cytotoxic action of acety1-11-keto-β-boswellic acid (AKBA) on meningioma cells. Planta Medica 2002; 68:397–401.PubMedCrossRefGoogle Scholar
  17. 17.
    Glaser T, Winter S, Groscurth P, et al: Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999; 80:756–765.PubMedCrossRefGoogle Scholar
  18. 18.
    Park YS, Lee JH, Barnett GH, Bondar J, Harwalkar JA, Safayhi H, Golubic M: Frankincense-derived boswellic acids inhibit growth and motility of brain tumor cells. Complementary Therapies Med 2002; 10:117–118.Google Scholar
  19. 19.
    Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker DK: Boswellic acids inhibit glioma growth: a new treatment option? J Neurooncol 2000; 46: 97–103.PubMedCrossRefGoogle Scholar
  20. 20.
    Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996; 97:806–813.PubMedCrossRefGoogle Scholar
  21. 21.
    Hennig R, Ding X-Z, Tong W-G, Schneider MB, Standop J, Friess H, Buchler MW, Pour PM, Adrian TE: 5-Lipoxygenase and Leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161:421–428.PubMedCrossRefGoogle Scholar
  22. 22.
    Nielsen CK, Ohd JF, Sjolander A: The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. In Advances in Prostaglandin, Leukotriene and Other Bioactive Lipid Research: Basic Science and Clinical Applicaions, 2003, Kluwer Academic Plenum Publishers, New York (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Mladen Golubic
    • 1
  • Richard A. Prayson
    • 2
  • Linda Vargo
    • 3
  • Judy Bondar
    • 4
  • Gene H. Barnett
    • 5
  1. 1.Brain Tumor InstituteCleveland Clinic FoundationClevelandUSA
  2. 2.Department of Anatomic Pathology/L25Cleveland Clinic FoundationClevelandUSA
  3. 3.Digital Imaging Core/NB10Cleveland Clinic FoundationClevelandUSA
  4. 4.Brain Tumor Institute/ND4-52ACleveland Clinic FoundationClevelandUSA
  5. 5.Brain Tumor Institute/S80Cleveland Clinic FoundationClevelandUSA

Personalised recommendations